Press Release: European Medicines Agency recommends approval of first vaccine for meningitis B

Author (Corporate)
Series Title
Series Details EMA/CHMP/728052/2012 (16.11.12)
Publication Date 16/11/2012
Content Type

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in November 2012, recommended the granting of a marketing authorisation for Bexsero, a new vaccine intended for the immunisation of individuals over two months of age against invasive meningococcal disease caused by Neisseria meningitidis group B.

The applicant for Bexsero is Novartis.
Source Link http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/11/news_detail_001656.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release: EMA/CHMP/728052/2012 (16.11.12) http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2012/11/WC500134846.pdf
Subject Categories
Countries / Regions